Articles tagged "Immunosuppression"

2018 American Transplant Congress
Immunophenotype of Cells Infiltrating the Graft Explains the Benefits of Belatacept
J. Furuzawa-Carballeda,¹ N. Uribe-Uribe,² G. Mondragon-Ramirez,⁴ J. Arreola-Guerra,⁵ R. Reyes-Acevedo,⁵ M. Vilatoba,³ R. Chavez-Fernandez,¹ F. Lopez-Verdugo,¹ A. Lopez-Toledo,⁴ G. Mondragon-Salgado,⁴ J. Alberu.³
¹Immunology, Inst. Nal. C. Medicas y Nutricion SZ, Mexico City, Mexico; ²Pathology, Inst. Nal. C. Medicas y Nutricion SZ, Mexico City, Mexico; ³Transplantation, Inst. Nal. C. Medicas y Nutricion SZ, Mexico City, Mexico; ⁴Inst Mex de Trasplantes, Cuernavaca, Mexico; ⁵Transplantation, C. Hospital Miguel Hidalgo, Aguascalientes, Mexico.
Previously, we found greater amounts of FoxP3 cells and lower amounts of CD4+/IL-17A+ and senescent cells in belatacept (Bela) patients compared to patients under cyclosporine…
2018 American Transplant Congress
Burden of Infectious Complications after Upper Extremity Allotransplantation: A Matched Cohort Study
A. Conrad,^1,2,3 P. Petruzzo,^4,5 J. Kanitakis,⁶ A. Gazarian,⁷ L. Badet,^3,8 P. Vanhems,^3,9 O. Thaunat,^1,3,10 E. Morelon,^1,3,10 A. Sicard.^1,3
¹Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon (HCL), Lyon, France; ²Department of Infectious Diseases and Tropical Medicine, HCL, Lyon, France; ³Claude Bernard Lyon 1 University, Lyon, France; ⁴Department of Transplantation, HCL, Lyon, France; ⁵Department of Surgery, University of Cagliari, Cagliari, Italy; ⁶Department of Dermatology, HCL, Lyon, France; ⁷Clinique du Parc, Lyon, France; ⁸Department of Urology and Transplantation, HCL, Lyon, France; ⁹Infection Control and Epidemiology Unit, HCL, Lyon, France; ¹⁰INSERM U1111, International Center for Infectiology Research, Lyon, France.
This study aimed to assess the infectious risk after upper extremity allotransplantation (UEA), a non-vital transplantation procedure requiring lifelong immunosuppression. A matched cohort study was…
2018 American Transplant Congress
Efficacy and Safety of Bleselumab in Kidney Transplant Recipients: A Phase 2, Randomized, Open-Label Study
R. Harland,¹ G. Klintmalm,² S. Jensik,³ H. Yang,⁴ J. Bromberg,⁵ J. Holman,⁶ M. Anil Kumar,⁶ V. Santos,⁶ T. Larson,⁶ X. Wang.⁶
¹University of Arizona, Tucson; ²Annette C. and Harold C. Simmons Transplant Institute, Dallas; ³Rush University, Chicago; ⁴PinnacleHealth Transplant Associates, Harrisburg; ⁵University of Maryland, Baltimore; ⁶Astellas Pharma Global Development, Inc., Northbrook.
Introduction: Bleselumab (ASKP1240) is an anti-CD40 monoclonal antibody currently in development. This phase 2, randomized, open-label study assessed the efficacy and safety of bleselumab in…
2018 American Transplant Congress
Opportunistic Infections after Kidney Transplantation Are Independent Risk Factor of Kidney Allograft Loss: A Retrospective Cohort Study
P. Attias,¹ G. Melica,² E. Audureau,³ D. Boutboul,⁵ N. De Castro,⁴ S. Gallien,² P. Grimbert,¹ M. Matignon.¹
¹Nephrology Transplantation, APHP Henri Mondor, Créteil, France; ²Infectious Diseases, APHP Henri Mondor, Créteil, France; ³Public Health, APHP Henri Mondor, Créteil, France; ⁴Infectious Diseases, APHP Saint-Louis, Paris, France; ⁵Immunology, APHP Saint-Louis, Paris, France.
BackgroundCurrently, kidney allograft survival improved, use of depleting antibodies increased anddonor and recipient became older. In this context, no recent study reported epidemiology of opportunistic…
2018 American Transplant Congress
The Effect of Steroid Maintenance in Recipients with Pancreas Transplant Alone: A Single Center Experience
J. Choi, J. Jung, H. Kwon, S. Shin, Y. Kim, D. Han.
Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University Ulsan College of Medicine, Seoul, Korea.
Background: In solid organ transplantation, the use of steroids for maintenance therapy is common. However, the appropriateness of steroid maintenance or withdrawal in pancreas transplantation…
2018 American Transplant Congress
Safety and Efficacy of Real-World Use of Everolimus for Kidney Transplant Patients: Post-Marketing Surveillance in Japan
H. Harada,¹ Y. Watarai,² J. Uchida,³ O. Kamisawa.⁴
¹Sapporo City General Hospital, Sapporo, Japan; ²Nagoya Daini Red Cross Hospital, Nagaya, Japan; ³Osaka City University, Osaka, Japan; ⁴Novartis Pharma K.K., Tokyo, Japan.
Background and purpose: After the approval of everolimus (EVR) in 2011 in Japan to prevent organ rejection in kidney transplant (KTx) patients, no data on…
2018 American Transplant Congress
Medicare Part D Plans Deny Coverage for Off-Label and Off-Compendia Immunosuppressant Use: A Case Series
L. Potter, E. Garrity.
Pharmacy, University of Chicago Medicine, Chicago, IL; Pulmonary & Critical Care Medicine, University of Chicago Medicine, Chicago, IL.
Immunosuppressants are a protected drug class under the Medicare Part D benefit, meaning that all drugs in this class must be present on all plan…
2018 American Transplant Congress
Steroid Avoidance in Renal Transplant Patients Treated with Everolimus and Low-Exposure Tacrolimus
T. Sandes-Freitas,^1,2 M. Sales,¹ J. Oliveira,¹ M. Oliveira,¹ G. Dantas,² C. Girão,¹ R. Esmeraldo.¹
¹Hospital Geral de Fortaleza, Fortaleza, Ceara, Brazil; ²Universidade Federal do Ceara, Fortaleza, Ceara, Brazil.
Background: Previous studies reported efficacy and safety of steroid-free regimens after kidney transplant (KT). However, there is no robust evidence on this strategy in patients…
2018 American Transplant Congress
Urinary CXCL9 Monitoring to Accompany a Safe CNI-to-Belatacept Conversion in Kidney Transplant Patients
P. Malvezzi,¹ C. Fischman,² T. Jouve,¹ B. Janbon,¹ P. Heeger,² L. Rostaing,¹ P. Cravedi.²
¹Service de Néphrologie, Dialyse, Aphérèses et Transplantation, CHU Grenoble Alpes, Grenoble, France; ²Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Background: Converting renal transplant recipients from CNI to belatacept immunosuppression has been proposed as a strategy to limit nephrotoxicity, but it is associated with an…
2018 American Transplant Congress
Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus
M. Gastaca,¹ J. Bustamante,² A. Ventoso,¹ J. Fernandez,² P. Ruiz,¹ M. Testillano,² M. Prieto,¹ P. Salvador,² I. Palomares,¹ M. Senosiain,² M. Suarez,² A. Valdivieso.¹
¹Hepatobiliary Surgery and Liver Transplant Unit, Cruces University Hospital, Bilbao, Spain; ²Hepatology Unit, Cruces University Hospital, Bilbao, Spain.
AIM: To describe the long-term outcome of liver transplantation (LT) in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo…